|
Updated
Perinatal Guidelines from the National Institutes of Health
The Public
Health Service Task Force Perinatal treatment guidelines have been
revised by the Perinatal HIV Guidelines Working Group. The updated
guidelines are entitled “Recommendations for Use of Antiretroviral
Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions
to Reduce Perinatal HIV-1 Transmission in the United States."
The revised document contains recommendations on the following:
·
Updated
information on nevirapine
(Viramune) and hepatic/rash
toxicity and recommendations regarding the use of nevirapine-based
HAART for prevention
of mother-to-child transmission of HIV.
·
Updates
to Clinical Scenario #1 regarding the use of efavirenz
(Sustiva) and nevirapine during pregnancy
and change in efavirenz's FDA Pregnancy Classification (reclassified
to Pregnancy Class D—positive evidence of fetal harm).
·
Updates
to the abacavir
(Ziagen), lamivudine (Epivir),
stavudine
(Zerit), zidovudine
(Retrovir), efavirenz, nevirapine, indinavir
(Crixivan), and nelfinavir
(Viracept) sections of the "Safety and Toxicity
of Individual Antiretroviral Agents in Pregnancy" supplement.
All
new information is highlighted
in the document.
The updated
guidelines document is available in the PERINATAL GUIDELINES section
of the GUIDELINES page on the AIDSinfo Web site at http://aidsinfo.nih.gov.
You
can download guidelines or you can request to receive the guidelines
by e-mail or regular mail on the AIDSinfo Web site.
Your
feedback is important!
The
Perinatal HIV Guidelines Working Group would like to hear your feedback
on the latest revisions to the "Recommendations for Use of
Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal
Health and Interventions to Reduce Perinatal HIV-1 Transmission
in the United States." Please send your comments with the subject
line "Perinatal Comments" to AIDSinfoWebmaster@aidsinfo.nih.gov by
March 10, 2005.
02/25/05
Source
http://aidsinfo.nih.gov.
Link to Index of All HIV and AIDS
Articles by Topic
|
